PLSE stock icon

Pulse Biosciences

20.54 USD
-0.34
1.63%
Updated Dec 3, 1:26 PM EST
1 day
-1.63%
5 days
14.75%
1 month
35.22%
3 months
20.12%
6 months
51.14%
Year to date
86.39%
1 year
100.00%
5 years
46.19%
10 years
392.57%
 

About: Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Employees: 56

0
Funds holding %
of 6,780 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

120% more call options, than puts

Call options by funds: $3.34M | Put options by funds: $1.52M

81% more capital invested

Capital invested by funds: $54.5M [Q2] → $98.4M (+$43.9M) [Q3]

26% more funds holding

Funds holding: 57 [Q2] → 72 (+15) [Q3]

22% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 18

0.35% more ownership

Funds ownership: 8.82% [Q2] → 9.17% (+0.35%) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for PLSE.

Financial journalist opinion

Neutral
Business Wire
1 month ago
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia presented these excellent results today at the 2024 American Thyroid Association Annual Meeting. The preliminary data demonstrate.
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
Neutral
Seeking Alpha
1 month ago
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations Burke Barrett - President & Chief Executive Officer Mike Koffler - Vice President, Finance Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript
Neutral
Business Wire
1 month ago
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with com.
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
Neutral
Business Wire
1 month ago
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Bi.
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
Neutral
Business Wire
1 month ago
Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-877-407-0752 for domestic cal.
Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024
Neutral
InvestorPlace
3 months ago
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024
Pulse Biosciences (NASDAQ: PLSE ) just reported results for the second quarter of 2024. Pulse Biosciences reported earnings per share of -20 cents.
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024
Neutral
Seeking Alpha
3 months ago
Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffler - VP of Finance Conference Call Participants Anthony Petrone - Mizuho Group Operator Greetings, and welcome to the Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript
Neutral
Business Wire
3 months ago
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, today announced business updates and preliminary financial results for the second quarter ended June 30, 2024. Recent Business Highlights Soft Tissue Ablation Completed the first procedure with the Percutaneous Electrode System in the United States following U.S. FDA 510(k) clearance for the.
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
Neutral
Business Wire
3 months ago
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. “We are thrilled to have Paul join the Pulse Biosciences Board. His track reco.
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
Neutral
Business Wire
3 months ago
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced treatment of the first two patients in the first-in-human feasibility study using its novel Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation. Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company'.
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
Charts implemented using Lightweight Charts™